Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma
- 26 September 2007
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 2 (1) , 89-94
Abstract
Background Antiviral treatments for hepatitis B virus (HBV) are not established in patients with HBV-related hepatocellular carcinoma (HCC). Aim To investigate the safety and efficacy of lamivudine (LAM) in patients with HBV-related HCC who were treated with radiofrequency ablation (RFA). Methods RFA-treated patients with HBV-related HCC were retrospectively divided into those who received LAM (LAM group) and those who did not (nontreatment group). The first-year changes in serum alanine aminotransferase (ALT), total bilirubin (TBIL), and albumin (ALB) levels were compared in corresponding subsets based on Child-Pugh classification (Mann–Whitney U test) and between one-to-one matched pairs (Wilcoxon signed rank test), who were selected on the basis of their propensity scores for receiving LAM. Overall and recurrence-free survival was also compared. Results Complete ablation of HCC was achieved in 104 patients with HBV-related HCC between January 2000 and December 2005. LAM was administered to 33 patients after RFA. Serum HBV-DNA became negative by TMA method in 24 (73%) patients. Four patients showed redetection of HBV-DNA with ALT elevation. Subset analysis based on initial Child-Pugh class and paired analysis with matching revealed significant decreases in ALT and bilirubin levels and increases in ALB levels in the first year in the LAM group (ΔALT = −17, ΔALB = +0.3, and ΔTBIL = −0.2) compared with controls (ΔALT = +5, ΔALB = ±0.0, and ΔTBIL = +0.3). Overall survival and recurrence-free survival did not differ between the two groups. No specific adverse effect was observed in the LAM group. Conclusion LAM after RFA for HBV-related HCC was safe and improved liver function. Further studies are needed to evaluate its effect on survival.Keywords
This publication has 23 references indexed in Scilit:
- Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markersHepatology, 2006
- Percutaneous radiofrequency ablation for hepatocellular carcinomaCancer, 2005
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis BNew England Journal of Medicine, 2003
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis BNew England Journal of Medicine, 2003
- Lamivudine Treatment Is Beneficial in Patients With Severely Decompensated Cirrhosis and Actively Replicating Hepatitis B Infection Awaiting Liver Transplantation: A Comparative Study Using A Matched, Untreated CohortHepatology, 2001
- Extended Lamivudine Treatment in Patients With Chronic Hepatitis B Enhances Hepatitis B E Antigen Seroconversion Rates: Results After 3 Years of TherapyHepatology, 2001
- Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis BHepatology, 2000
- Treatment of Chronic Hepatitis B InfectionNew England Journal of Medicine, 1998
- Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in JapanHepatology, 1995